Zacks Investment Research
21 Jul 2026, 14:55 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Wall Street analysts have a mean short-term price target of $62.55 for Maze Therapeutics (MAZE), representing a potential 120.5% upside from its current price of $28.37. — A consensus price target indicating more than double the current value typically attracts bullish investor sentiment.
+0.60There is a positive trend in earnings estimate revisions for Maze Therapeutics, with analysts agreeing the company will report better earnings than previously estimated. — Upward earnings revisions are a strong fundamental signal that often precedes price appreciation.
+0.40Maze Therapeutics shares have increased by 11% over the past four weeks. — Recent price momentum suggests growing market interest, though it is a lagging indicator compared to targets.
+0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The article highlights significant potential upside with a mean price target suggesting 120.5% growth and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
4h ago
